Skip to content

S. 775 · 118th Congress (2023–2025)

Increasing Transparency in Generic Drug Applications Act

This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.

Show official title

A bill to provide for increased transparency in generic drug applications.

Expired in Senate committee

Derived from the legislative history, not an official disposition.

Latest actionReferred to committee

This bill’s path

This is S. 775’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed Senate

  3. Passed House

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Sen. Margaret Wood Hassan (D-NH)
Cosponsors
3 cosponsors

1 original · 2 later

  1. Sen. Rand Paul (R-KY)· Original · Mar 14, 2023
  2. Sen. Mike Braun (R-IN)· Later · Mar 28, 2023
  3. Sen. John W. Hickenlooper (D-CO)· Later · Apr 25, 2023
Policy area
Health
Subjects
  • Administrative law and regulatory procedures
  • Department of Health and Human Services
  • Drug safety, medical device, and laboratory regulation
  • Prescription drugs

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in Senate

    Document: Introduced in Senate

    Sources
  2. Latest

    Referred to committee

    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

    Sources
  3. Expired

    Introduced → Referred to Senate Health, Education, Labor, and Pensions → No further action before the 118th Congress ended.

Committees

  1. SenateHealth, Education, Labor, and PensionsReferred Mar 14, 2023

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in Senate
Titles (2)
  1. Increasing Transparency in Generic Drug Applications Act

    Display title, Short title · Introduced in Senate

  2. A bill to provide for increased transparency in generic drug applications.

    Official title · Introduced in Senate